1
|
Eisterer W, Gerger A, Öhler L, Mlineritsch B, Sliwa T, Wilthoner K, Petzer A, Pichler P, Hubmann E, Winder T, Burgstaller S, Korger M, Andel J, Wöll E, Neumann H, Pecherstorfer M, Philipp-Abbrederis K, Djanani A, Gruenberger B, Längle F, Prager G. Austrian real world data in elderly and younger metastatic pancreatic cancer patients: Interim results of a multicenter non-interventional study with nab-paclitaxel/gemcitabine. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
2
|
Steger G, Petru E, Haslbauer F, Marth C, Egle D, Galid A, Sliwa T, Lang A, Kuehr T, Petzer A, Ruckser R, Greil R, Mlineritsch B, Singer C, Seifert M, Andel J, Kwasny W, Pichler P, Tinchon C, Bartsch R. Real-World multicenter Austrian analysis of the safety and effectiveness of nab-paclitaxel in young and elderly patients with metastatic breast cancer. Eur J Cancer 2018. [DOI: 10.1016/s0959-8049(18)30519-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
3
|
Aapro M, Boccia R, Choquet S, Hus I, Link H, Sliwa T. Optimal use of pegfilgrastim (a long-acting granulocyte-colony stimulating factor [G-CSF]) to manage chemotherapy-induced febrile neutropenia (FN) in haematological malignancies: consensus guidance recommendations. Eur J Cancer 2017. [DOI: 10.1016/s0959-8049(17)30619-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
4
|
Steger G, Petru E, Haslbauer F, Egle D, Galid A, Sliwa T, Lang A, Kühr T, Petzer A, Ruckser R, Mlineritsch B, Greil R, Seifert M, Singer C, Andel J, Kwasny W, Marth C, Pichler P, Tinchon C, Bartsch R. Safety and effectiveness of nab-paclitaxel in young and elderly patients with metastatic breast cancer: a prospective, multicenter non-interventional study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw365.20] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
5
|
Geissler K, Jäger E, Barna A, Alendar T, Ljubuncic E, Sliwa T, Valent P. Chronic myelomonocytic leukemia patients with RAS pathway mutations show high in vitro myeloid colony formation in the absence of exogenous growth factors. Leukemia 2016; 30:2280-2281. [PMID: 27585952 PMCID: PMC5097063 DOI: 10.1038/leu.2016.235] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- K Geissler
- Fifth Medical Department with Hematology, Oncology and Palliative Medicine, Hospital Hietzing, Vienna, Austria
| | - E Jäger
- Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
| | - A Barna
- Blood Transfusion Service for Upper Austria, Austrian Red Cross, Linz, Austria
| | - T Alendar
- Fifth Medical Department with Hematology, Oncology and Palliative Medicine, Hospital Hietzing, Vienna, Austria
| | - E Ljubuncic
- Fifth Medical Department with Hematology, Oncology and Palliative Medicine, Hospital Hietzing, Vienna, Austria
| | - T Sliwa
- Third Medical Department, Hanusch Hospital, Vienna, Austria
| | - P Valent
- Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
| |
Collapse
|
6
|
Mikołajczyk TP, Osmenda G, Batko B, Wilk G, Krezelok M, Skiba D, Sliwa T, Pryjma JR, Guzik TJ. Heterogeneity of peripheral blood monocytes, endothelial dysfunction and subclinical atherosclerosis in patients with systemic lupus erythematosus. Lupus 2015; 25:18-27. [PMID: 26251402 DOI: 10.1177/0961203315598014] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2014] [Accepted: 06/29/2015] [Indexed: 11/16/2022]
Abstract
BACKGROUND Systemic lupus erythematosus (SLE) is characterized by increased cardiovascular morbidity and mortality. SLE patients have increased prevalence of subclinical atherosclerosis, although the mechanisms of this observation remain unclear. Considering the emerging role of monocytes in atherosclerosis, we aimed to investigate the relationship between subclinical atherosclerosis, endothelial dysfunction and the phenotype of peripheral blood monocytes in SLE patients. METHODS We characterized the phenotype of monocyte subsets defined by the expression of CD14 and CD16 in 42 patients with SLE and 42 non-SLE controls. Using ultrasonography, intima-media thickness (IMT) of carotid arteries and brachial artery flow-mediated dilation (FMD) as well as nitroglycerin-induced dilation (NMD) were assessed. RESULTS Patients with SLE had significantly, but only modestly, increased IMT when compared with non-SLE controls (median (25th/75th percentile) 0.65 (0.60/0.71) mm vs 0.60 (0.56/0.68) mm; p < 0.05). Importantly, in spite of early atherosclerotic complications in the studied SLE group, marked endothelial dysfunction was observed. CD14dimCD16+proinflammatory cell subpopulation was positively correlated with IMT in SLE patients. This phenomenon was not observed in control individuals. Interestingly, endothelial dysfunction assessed by FMD was not correlated with any of the studied monocyte subsets. CONCLUSIONS Our observations suggest that CD14dimCD16+monocytes are associated with subclinical atherosclerosis in SLE, although the mechanism appears to be independent of endothelial dysfunction.
Collapse
Affiliation(s)
- T P Mikołajczyk
- Translational Medicine Laboratory, Department of Internal Medicine, Jagiellonian University School of Medicine, Krakow, Poland
| | - G Osmenda
- Translational Medicine Laboratory, Department of Internal Medicine, Jagiellonian University School of Medicine, Krakow, Poland
| | - B Batko
- Division of Rheumatology, J Dietl Clinical Hospital, Krakow, Poland
| | - G Wilk
- Translational Medicine Laboratory, Department of Internal Medicine, Jagiellonian University School of Medicine, Krakow, Poland
| | - M Krezelok
- Division of Rheumatology, J Dietl Clinical Hospital, Krakow, Poland
| | - D Skiba
- Translational Medicine Laboratory, Department of Internal Medicine, Jagiellonian University School of Medicine, Krakow, Poland Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK
| | - T Sliwa
- Translational Medicine Laboratory, Department of Internal Medicine, Jagiellonian University School of Medicine, Krakow, Poland
| | - J R Pryjma
- Department of Immunology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland
| | - T J Guzik
- Translational Medicine Laboratory, Department of Internal Medicine, Jagiellonian University School of Medicine, Krakow, Poland Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK
| |
Collapse
|
7
|
Ignacak A, Kasztelnik M, Sliwa T, Korbut RA, Rajda K, Guzik TJ. Prolactin--not only lactotrophin. A "new" view of the "old" hormone. J Physiol Pharmacol 2012; 63:435-443. [PMID: 23211297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 12/13/2010] [Accepted: 09/18/2012] [Indexed: 06/01/2023]
Abstract
Prolactin (PRL) is a hormone mainly secreted by the anterior pituitary. Recent studies have shown that it may also be produced by many extrapituitary cells. The PRL gene expression is controlled by two independent promoter regions, which may be differentially regulated in the pituitary and extrapituitary organs. Proteolytic modifications of PRL generate variants of the hormone. A16 kDa PRL fragment, acting through a specific receptor, has both an antiangiogenic activity as well as an inhibitory effect on tumor growth. Stimulation of the PRL receptor involves many signal transduction pathways, for example JAK2/STAT, MAPK, c-src and Fyn kinase cascade, and these pathways may vary in different tissues. PRL synthesis and secretion is mainly regulated by the inhibitory influence of dopamine but other hormones are also involved in these mechanisms. The essential biological action of PRL is the stimulation of lactogenesis and galactopoesis. Apart from its classical functions, PRL affects other aspects of human body function including osmoregulation, metabolism and regulation of the immune and the central nervous system. Hyperprolactinemia is a common syndrome affecting both men and women. It is manifested by the presence of galactorrhoea and through the symptoms of hypogonadotrophic hypogonadism. Following on from the fact that PRL has so many pleiotropic tissue specific effects it is not surprising to learn that hyperprolactinaemia is a systemic condition which may predispose to numerous cardiovascular and immune-mediated reactions. The exact effects of PRL on both immune and cardiovascular systems are being currently unraveled and may lead to the introduction of novel therapeutic approaches in the future.
Collapse
Affiliation(s)
- A Ignacak
- Department of Internal and Agricultural Medicine and Institute of Pharmacology, Jagiellonian University School of Medicine, Cracow, Poland.
| | | | | | | | | | | |
Collapse
|
8
|
Resch G, Schaberl-Moser R, Kier P, Kopetzky G, Scheithauer W, Sliwa T, Greil R, Nösslinger T, Mayrbäurl B, Thaler J. Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe. Ann Oncol 2011; 22:486-7. [PMID: 21239398 DOI: 10.1093/annonc/mdq744] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|